Screening outcomes in older US women undergoing multiple mammograms in community practice: Does interval, age, or comorbidity score affect tumor characteristics or false positive rates?

78Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Uncertainty exists about the appropriate use of screening mammography among older women because comorbid illnesses may diminish the benefit of screening. We examined the risk of adverse tumor characteristics and false positive rates according to screening interval, age, and comorbidity. Methods: From January 1999 to December 2006, data were collected prospectively on 2993 older women with breast cancer and 137 949 older women without breast cancer who underwent mammography at facilities that participated in a data linkage between the Breast Cancer Surveillance Consortium and Medicare claims. Women were aged 66 to 89 years at study entry to allow for measurement of 1 year of preexisting illnesses. We used logistic regression analyses to calculate the odds of advanced (IIb, III, IV) stage, large (>20 millimeters) tumors, and 10-year cumulative probability of false-positive mammography by screening frequency (1 vs 2 years), age, and comorbidity score. The comorbidity score was derived using the Klabunde approximation of the Charlson score. All statistical tests were two-sided. Results: Adverse tumor characteristics did not differ statistically significantly by comorbidity, age, or interval. Cumulative probability of a false-positive mammography result was higher among annual screeners than biennial screeners irrespective of comorbidity: 48.0% (95% confidence interval [CI] = 46.1% to 49.9%) of annual screeners aged 66 to 74 years had a false-positive result compared with 29.0% (95% CI = 28.1% to 29.9%) of biennial screeners.ConclusionWomen aged 66 to 89 years who undergo biennial screening mammography have similar risk of advanced-stage disease and lower cumulative risk of a false-positive recommendation than annual screeners, regardless of comorbidity. © The Author 2013. Published by Oxford University Press. All rights reserved.

References Powered by Scopus

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

40766Citations
N/AReaders
Get full text

Validation of a combined comorbidity index

5449Citations
N/AReaders
Get full text

Development of a comorbidity index using physician claims data

1671Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Breast cancer screening for women at average risk: 2015 Guideline update from the American cancer society

1360Citations
N/AReaders
Get full text

Benefits and harms of breast cancer screening: A systematic review

485Citations
N/AReaders
Get full text

A systematic assessment of benefits and risks to guide breast cancer screening decisions

379Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Braithwaite, D., Zhu, W., Hubbard, R. A., O’Meara, E. S., Miglioretti, D. L., Geller, B., … Kerlikowske, K. (2013). Screening outcomes in older US women undergoing multiple mammograms in community practice: Does interval, age, or comorbidity score affect tumor characteristics or false positive rates? Journal of the National Cancer Institute, 105(5), 334–341. https://doi.org/10.1093/jnci/djs645

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 27

55%

Researcher 14

29%

Professor / Associate Prof. 5

10%

Lecturer / Post doc 3

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 34

77%

Nursing and Health Professions 4

9%

Agricultural and Biological Sciences 4

9%

Pharmacology, Toxicology and Pharmaceut... 2

5%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free